Novo Nordisk's Weight-Loss Drug Pipeline Suffers Setback

Wegovy and Ozempic maker Novo Nordisk faces a major setback as its highly anticipated CagriSema drug is labeled 'obsolete' after disappointing clinical trial results.

Novo Nordisk, the pharmaceutical company behind the popular weight-loss medications Wegovy and Ozempic, has suffered a significant blow as its next-generation weight-loss drug, CagriSema, has been labeled

Novo Nordisk's Next-Gen Weight-Loss Drug Fails to Impress, Shares Plummet

Comments (0)

Related Articles

Repurposed Drug May Boost Survival in Aggressive Ovarian Cancer

Doctors' Leader Blames Reduced Pay Offer for Ongoing Strikes in England

Groundbreaking Access Consortium Launches Pilot Program

Related Articles

Health
Repurposed Drug May Boost Survival in Aggressive Ovarian Cancer
A drug used for Cushing's syndrome could extend life expectancy for patients with platinum-resistant ovarian cancer, according to a new clinical trial.
about 9 hours ago00

Health
Doctors' Leader Blames Reduced Pay Offer for Ongoing Strikes in England
Resident doctors' leader claims last-minute pay cut by ministers derailed potential deal, forcing 15th strike disrupting NHS services.
about 12 hours ago00
about 12 hours ago00

Health
Groundbreaking Access Consortium Launches Pilot Program
The Access Consortium unveils an innovative work-sharing pathway to fast-track priority medical procedures, revolutionizing global healthcare collaboration.
about 13 hours ago00
about 13 hours ago00